WO2008120765A1 - Composition analgésique - Google Patents

Composition analgésique Download PDF

Info

Publication number
WO2008120765A1
WO2008120765A1 PCT/JP2008/056239 JP2008056239W WO2008120765A1 WO 2008120765 A1 WO2008120765 A1 WO 2008120765A1 JP 2008056239 W JP2008056239 W JP 2008056239W WO 2008120765 A1 WO2008120765 A1 WO 2008120765A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
propionic
vitamin
analgesic
components
Prior art date
Application number
PCT/JP2008/056239
Other languages
English (en)
Japanese (ja)
Inventor
Manabu Nozaki
Shigeki Sawamura
Original Assignee
Kobayashi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co., Ltd. filed Critical Kobayashi Pharmaceutical Co., Ltd.
Publication of WO2008120765A1 publication Critical patent/WO2008120765A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention vise à proposer une composition analgésique qui peut améliorer l'effet analgésique d'un agent analgésique de type acide propionique tel que l'ibuprofène contenu dans celui-ci et a une excellente sécurité. A cet effet, la composition comprend un agent analgésique de type acide propionique et deux composants de vitamine B ou plus. La quantité totale des composants de vitamine B est, de préférence, de 0,001 à 100 parties en poids par rapport à 1 partie en poids de l'agent analgésique de type acide propionique. L'agent analgésique de type acide propionique est, de préférence, l'ibuprofène. Les composants de vitamine B comprennent, de préférence, au moins la vitamine B12 ou l'acide folique.
PCT/JP2008/056239 2007-03-30 2008-03-28 Composition analgésique WO2008120765A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-091793 2007-03-30
JP2007091793A JP5161472B2 (ja) 2007-03-30 2007-03-30 鎮痛用組成物

Publications (1)

Publication Number Publication Date
WO2008120765A1 true WO2008120765A1 (fr) 2008-10-09

Family

ID=39808345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056239 WO2008120765A1 (fr) 2007-03-30 2008-03-28 Composition analgésique

Country Status (2)

Country Link
JP (1) JP5161472B2 (fr)
WO (1) WO2008120765A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018076305A (ja) * 2016-10-31 2018-05-17 エスエス製薬株式会社 医薬組成物
WO2021037874A1 (fr) * 2019-08-26 2021-03-04 Dsm Ip Assets B.V. Forme pharmaceutique orale solide comprenant du naproxène et de la vitamine b12
WO2021037871A1 (fr) * 2019-08-26 2021-03-04 Dsm Ip Assets B.V. Forme posologique orale solide comprenant du naproxène et de la vitamine b6

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011168580A (ja) * 2010-01-19 2011-09-01 Daiichi Sankyo Healthcare Co Ltd 医薬組成物
JP6106359B2 (ja) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP7026457B2 (ja) * 2016-07-07 2022-02-28 第一三共ヘルスケア株式会社 ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050028A1 (fr) * 1999-02-24 2000-08-31 Andrew Peter Worsley Compositions pour le traitement de la douleur
WO2000056404A1 (fr) * 1999-03-24 2000-09-28 Kilgowan Limited Formulations pour le traitement de la douleur contenant de la vitamine b12 et de la phenylanine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050028A1 (fr) * 1999-02-24 2000-08-31 Andrew Peter Worsley Compositions pour le traitement de la douleur
WO2000056404A1 (fr) * 1999-03-24 2000-09-28 Kilgowan Limited Formulations pour le traitement de la douleur contenant de la vitamine b12 et de la phenylanine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUGGEMAN G. ET AL.: "Results of a double-blind study of diclofenac + vitamin B1, B6, B12 versus diclofenac in patients with acute pain of the lumbar vertebrae", KLIN. WOCHENSCHR., vol. 68, no. 2, 1990, pages 116 - 120 *
GLUECK C.J. ET AL.: "Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: a pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease", CLIN. APPL. THROMB. HEMOST., vol. 12, no. 4, 2006, pages 427 - 439 *
O'SHAUGHNESSY J.A. ET AL.: "Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer", CLIN. BREAST CANCER, vol. 6, no. 2, 2005, pages 143 - 149 *
TANAKA C.: "New Pharmacology, (4th revised edition)", 2002, NANKODO CO., LTD., pages: 484 - 485 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018076305A (ja) * 2016-10-31 2018-05-17 エスエス製薬株式会社 医薬組成物
WO2021037874A1 (fr) * 2019-08-26 2021-03-04 Dsm Ip Assets B.V. Forme pharmaceutique orale solide comprenant du naproxène et de la vitamine b12
WO2021037871A1 (fr) * 2019-08-26 2021-03-04 Dsm Ip Assets B.V. Forme posologique orale solide comprenant du naproxène et de la vitamine b6
CN114302713A (zh) * 2019-08-26 2022-04-08 帝斯曼知识产权资产管理有限公司 包含萘普生和维生素b6的固体口服剂型

Also Published As

Publication number Publication date
JP5161472B2 (ja) 2013-03-13
JP2008247822A (ja) 2008-10-16

Similar Documents

Publication Publication Date Title
WO2008120765A1 (fr) Composition analgésique
GB0514463D0 (en) Use of pinolenic acid
IL195030A (en) IV dpp inhibitor assemblies
WO2010054113A3 (fr) Antagonistes de cycloalkane[b]azaindole de récepteurs de la prostaglandine d2
WO2007077560A3 (fr) Compositions cryoprotectrices et procédés d'utilisation de celles-ci
WO2010037059A3 (fr) Antagonistes hétéroaryliques des récepteurs de prostaglandine d<sb>2</sb>
WO2010003127A3 (fr) Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
WO2010042652A3 (fr) Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
WO2012103038A3 (fr) Compositions de nanoparticules, leurs formulations et leurs utilisations
WO2009145989A3 (fr) Antagonistes d’aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
EP2123257A3 (fr) Système émulsifié stable polyol dans l'huile à teneur élevée en vitamine C et sa préparation
WO2009140642A3 (fr) Antagonistes tricycliques de récepteurs de prostaglandine d<sb>2</sb>
WO2010085820A3 (fr) Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine
CR10305A (es) "derivados sustituidos de cromanol y su uso.
WO2009044648A1 (fr) Agent anti-allergène
WO2008074824A3 (fr) Composés
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
WO2007044611A3 (fr) Methodes de gestion du poids
MX2011010547A (es) Composiciones farmaceuticas estables de diclofenaco.
MX2010001243A (es) Composicion anti-inflamatoria.
WO2009102707A3 (fr) Oxazaphosphorines substituées
WO2008010008A3 (fr) Combinaisons cardiovasculaires faisant appel à des inhibiteurs de rennine-angiotensine
WO2008155651A3 (fr) Composition supplémentaire comprenant de l'inositol pour contrôler l'induction de l'ovulation
WO2008070354A3 (fr) Benzidimidazole thiophènes substitués en 5 et 6 pour plk

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739357

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08739357

Country of ref document: EP

Kind code of ref document: A1